Maraganore John
SEC-identified person · CIK 1180432 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Kymera Therapeutics, Inc. KYMR | Director | filed 2022–2026 |
| Rapport Therapeutics, Inc. RAPP | Director | filed 2024–2026 |
| Beam Therapeutics Inc. BEAM | Director | filed 2021–2026 |
| Hemab Therapeutics Holdings, Inc. COAG | Director | filed 2026–2026 |
| Takeda Pharmaceutical CO LTD TAK | Director | filed 2026–2026 |
| Social Capital Suvretta Holdings Corp. III PROK | Director | filed 2022–2023 |
| Agios Pharmaceuticals, INC. AGIO | Director | filed 2013–2023 |
| Alnylam Pharmaceuticals, INC. ALNY | Director · President & CEO | filed 2006–2021 |
| Bluebird bio, Inc. BLUE | Director | filed 2013–2017 |
| Regulus Therapeutics Inc. RGLS | Director | filed 2012–2012 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.